Telix Pharmaceuticals (TLX) Liabilities and Shareholders Equity (2023 - 2024)
Telix Pharmaceuticals (TLX) posted quarterly Liabilities and Shareholders Equity of $1.1 billion for Q4 2024, up 273.54% year-on-year from $286.7 million in Q1 2024, and up 273.54% on a QoQ basis from $286.7 million in Q4 2023.
Telix Pharmaceuticals (TLX) Liabilities and Shareholders Equity (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Liabilities and Shareholders Equity for 2 consecutive years, with $1.1 billion the latest figure, recorded in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 286.70 Mn |